

Peter Meldgaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5166414/publications.pdf>

Version: 2024-02-01

63
papers

2,928
citations

331538

21
h-index

168321

53
g-index

63
all docs

63
docs citations

63
times ranked

5083
citing authors

#	ARTICLE	IF	CITATIONS
1	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. <i>Case Reports in Oncology</i> , 2022, 14, 1323-1327.	0.3	4
2	TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. <i>Lung Cancer</i> , 2022, 164, 23-32.	0.9	2
3	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. <i>Acta OncolÅ³gica</i> , 2022, 61, 409-416.	0.8	11
4	The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer - a randomised controlled trial. <i>Journal of Geriatric Oncology</i> , 2021, 12, 41-48.	0.5	15
5	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. <i>Clinical Lung Cancer</i> , 2021, 22, e870-e877.	1.1	6
6	Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20593-e20593.	0.8	0
7	<i>EGFR</i> transcription in nonâ€smallâ€cell lung cancer tumours can be revealed in ctDNA by cellâ€free chromatin immunoprecipitation (cfChIP). <i>Molecular Oncology</i> , 2021, 15, 2868-2876.	2.1	7
8	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€Real World Efficacy. <i>Cancers</i> , 2021, 13, 4846.	1.7	19
9	cGAS-STING pathway expression as a prognostic tool in NSCLC. <i>Translational Lung Cancer Research</i> , 2021, 10, 340-354.	1.3	18
10	Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). <i>Clinical Lung Cancer</i> , 2020, 21, e61-e64.	1.1	7
11	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 37-43.	0.9	24
12	Neurofilament Light Chain as A Biomarker for Brain Metastases. <i>Cancers</i> , 2020, 12, 2852.	1.7	20
13	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2020, 147, 244-251.	0.9	12
14	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. <i>Lung Cancer</i> , 2020, 143, 67-72.	0.9	17
15	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 947.	1.7	20
16	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 135, 92-96.	0.9	22
17	Intraâ€individual variation of circulating tumour DNA in lung cancer patients. <i>Molecular Oncology</i> , 2019, 13, 2098-2106.	2.1	14
18	Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancerâ€a follow-up study. <i>European Journal of Cancer</i> , 2019, 116, 27-34.	1.3	15

#	ARTICLE	IF	CITATIONS
19	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
20	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. <i>Clinical Lung Cancer</i> , 2019, 20, 161-166.e1.	1.1	13
21	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. <i>Translational Oncology</i> , 2019, 12, 432-440.	1.7	20
22	The prognostic role of inflammation-scores on overall survival in lung cancer patients. <i>Acta Oncologica</i> , 2019, 58, 371-376.	0.8	15
23	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
24	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. <i>BMC Cancer</i> , 2018, 18, 191.	1.1	14
25	Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity. <i>Journal of Thoracic Oncology</i> , 2018, 13, 54-62.	0.5	21
26	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. <i>Oncotarget</i> , 2018, 9, 31066-31076.	0.8	18
27	Frailty status but not age predicts complications in elderly cancer patients: a follow-up study. <i>Acta Oncologica</i> , 2018, 57, 1458-1466.	0.8	27
28	¹⁸ F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-small Cell Lung Cancer Patients: A Comparison of Assessment Methods. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1931-1937.	2.8	16
29	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 752-762.	0.5	17
30	Programmed Death Ligand 1 Expression in Paired Non-small Cell Lung Cancer Tumor Samples. <i>Clinical Lung Cancer</i> , 2017, 18, e473-e479.	1.1	35
31	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 704-709.	2.9	45
32	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. <i>Stem Cells International</i> , 2016, 2016, 1-8.	1.2	12
33	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. <i>Translational Oncology</i> , 2016, 9, 505-511.	1.7	13
34	PD-L1 Expression and Survival among Patients with Advanced Non-small Cell Lung Cancer Treated with Chemotherapy. <i>Translational Oncology</i> , 2016, 9, 64-69.	1.7	77
35	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 243-248.	0.6	2
36	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2016, 94, 81-87.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2016, 100, 77-84.	0.9	97
38	Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1701-1710.	0.5	213
39	Gene Expression of the EGF System as a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations. <i>Translational Oncology</i> , 2016, 9, 306-312.	1.7	7
40	The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial. <i>BMC Cancer</i> , 2015, 15, 934.	1.1	18
41	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	0.9	40
42	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. <i>Lung Cancer</i> , 2015, 88, 167-173.	0.9	13
43	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308
44	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. <i>Lung Cancer</i> , 2015, 90, 314-320.	0.9	13
45	Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 8049-8049.	0.8	0
46	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	0.6	210
47	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. <i>Cancer</i> , 2014, 120, 3896-3901.	2.0	180
48	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246
49	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	0.5	31
50	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230.	0.9	41
51	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	0.6	410
52	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2014, 85, 435-441.	0.9	11
53	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. <i>BMC Cancer</i> , 2014, 14, 294.	1.1	135
54	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine after surgery for NSCLC. <i>Journal of Clinical Oncology</i> , 2014, 32, e18501-e18501.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Surgery for NSCLC stages T1-3N2M0 having preoperative pathologically verified N2 involvement: A prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group.. Journal of Clinical Oncology, 2013, 31, 7504-7504.	0.8	14
56	The European Thoracic Oncology Platform Lungscope project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 7514-7514.	0.8	2
57	Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [18F]fluorodeoxyglucose-positron emission tomography/ computed tomography. Cancer Imaging, 2012, 12, 437-446.	1.2	8
58	Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2011, 6, 1287-1289.	0.5	124
59	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1946-1949.	0.5	12
60	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiotherapy and Oncology, 2004, 72, 139-145.	0.3	63
61	A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls. Clinica Chimica Acta, 2000, 290, 129-144.	0.5	3
62	Loss of abh antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus. International Journal of Cancer, 1995, 63, 341-344.	2.3	11
63	Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study. F1000Research, 0, 10, 673.	0.8	0